Duodenal carbidopa/levodopa: An opportunity for advanced Parkinson's disease patients

• Autores: Mónica Gayoso Rey, Luis Manuel López Díaz
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 5, 2013, págs. 362-364
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To describe the efficacy and safety of Levodopa-Carbidopa Intestinal Gel treatment (LCIG) in a patient with advanced Parkinson's Disease (PD) at a first level hospital. Method: Clinical data, disease progress and previous treatments to LCIG administration were gathered from the patient's electronic medical record. The Unified Parkinson's Disease Rating Scale (UPDRS) and the Schwab & England Activities of Daily Living Scale (ADL) were used for measuring the patient's response to LCIG. Results: After ambulatory oral levodopa/carbidopa, rasagiline and rotigotine treatment, the patient was hospitalized due to motor and non-motor fluctuations (anxiety, insomnia, dysphagia). During her stay, entacapone and apomorphine were added to the treatment with no response. Therefore, LCIG was administered. Conclusion: LCIG treatment caused an improvement in motor and non-motor fluctuations. Tube obstruction problems may cause treatment interruption